Rani Therapeutics Holdings Inc (NASDAQ:RANI)’s traded shares stood at 1.28 million during the latest session, with the company’s beta value hitting 0.16. At the last check today, the stock’s price was $1.58, to imply a decrease of -4.24% or -$0.07 in intraday trading. The RANI share’s 52-week high remains $8.75, putting it -453.8% down since that peak but still an impressive 21.52% since price per share fell to its 52-week low of $1.24. The company has a valuation of $90.74M, with an average of 3.49 million shares in intraday trading volume over the past 10 days and average of 992.05K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Rani Therapeutics Holdings Inc (RANI), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give RANI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.24.
Rani Therapeutics Holdings Inc (NASDAQ:RANI) trade information
After registering a -4.24% downside in the latest session, Rani Therapeutics Holdings Inc (RANI) has traded red over the past five days. The 5-day price performance for the stock is 13.67%, and 10.49% over 30 days. With these gigs, the year-to-date price performance is 15.33%. Short interest in Rani Therapeutics Holdings Inc (NASDAQ:RANI) saw shorts transact 1.49 million shares and set a 0.36 days time to cover.
The extremes give us $9 and $28 for target low and target high price respectively. As such, RANI has been trading -1672.15% off suggested target high and -469.62% from its likely low.
Rani Therapeutics Holdings Inc (RANI) estimates and forecasts
Looking at statistics comparing Rani Therapeutics Holdings Inc share performance against respective industry, we note that the company has outperformed competitors. Rani Therapeutics Holdings Inc (RANI) shares are -34.98% down over the last 6 months, with its year-to-date growth rate higher than industry average at 24.06% against 16.00%.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 0.28% for the past 5-year period. While 2025 is set for a 7.86% return in earnings, projections for the next 5 years are at 18.19% annually.
RANI Dividends
Rani Therapeutics Holdings Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Rani Therapeutics Holdings Inc (NASDAQ:RANI)’s Major holders
Rani Therapeutics Holdings Inc insiders hold 30.61% of total outstanding shares, with institutional holders owning 19.59% of the shares at 28.23% float percentage. In total, 19.59% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 0.71 million shares (or 2.7265% of shares), all amounting to roughly $2.7 million.
The next major institution holding the largest number of shares is NAN FUNG GROUP HOLDINGS LTD with 0.49 million shares, or about 1.8959% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.88 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Rani Therapeutics Holdings Inc (RANI) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 518.7 shares. This is just over 1.56% of the total shares, with a market valuation of $0.82 million. Data from the same date shows that the other fund manager holds a little less at 172.98, or 0.52% of the shares, all valued at about 0.27 million.
